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Thirty-six adult patients (16 women) with mild to moderate asthma with a mean baseline forced expiratory volume
in 1 sec (FEV1) of 73?8% (46–106%) of predicted normal value and mean reversibility of 24?2% (14?6–47?1%) were
included in this double-blind, double-dummy, randomized, placebo-controlled and cross-over study. The patients
inhaled single doses 4?5 or 9mg of formoterol (Oxis1) via Turbuhaler1 salbutamol (Ventolin1) 100 or 200 mg from
a pressurized metered dose inhaler (pMDI) or placebo at five randomized visits. Ecacy was measured by FEV1
pre-dose and then 1, 3, 5, 7, 10, 15, 20, 25 and 30min after inhalation of the study drug. The primary variable of
ecacy was the FEV1-value 3 min after dose intake.
No statistically significant dierences were found between active treatments. All active treatments gave a higher
bronchodilating eect at 3min than placebo: 10?0, 11?4% for salbutamol 100 and 200 mg and 11?7, 11?8% for
formoterol 4?5 and 9mg (P50?001 in all cases). There was a correlation between the measured response at 3min
and the subjective experience of the patients. The relative dierence vs. placebo remained throughout the study
period for all active treatments except for low dose salbutamol. All treatments were well tolerated.
In conclusion, formoterol Turbuhaler has as rapid an onset of action as salbutamol pMDI when given at
recommended doses.
Key words: onset; Oxis; formoterol; salbutamol; Turbuhaler; pMDI.
RESPIR. MED. (2000) 94, 607–611 # 2000 HARCOURT PUBLISHERS LTD
RESPIRATORY MEDICINE (2000) 94, 607–611
doi:10.1053/rmed.2000.0788, available online at http://www.idealibrary.com onIntroduction
Inhaled b2-agonists are used in the treatment of asthma
both as rescue medication and as regular prophylaxis. They
are divided into two groups: short-acting and long-acting
b2-agonists. Only the short-acting b2-agonists are recom-
mended to be used as needed for acute symptom relief in
patients with mild to more severe asthma (1). The
commonly used inhaled short-acting b2-agonists have a
disadvantage in having a duration of bronchodilation of
only 4–6 h (2). As the long-acting inhaled b2-agonists have a
duration of action of at least 12 h (3,4), it would be
beneficial to asthmatic patients if these drugs also could
show an onset of action comparable to that of the short-
acting inhaled b2-agonists.
Most of the previous observations on the onset of action
of formoterol have been made in comparison with the other
long-acting b2-agonists approved for regular daily use,
salmeterol. Salmeterol has been shown to have a slow onset
of action, whereas formoterol administered via a pMDI (5)Received 29 November 1999 and accepted in revised form 4
January 2000.
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onset of action. One study has compared formoterol
administered via a pMDI to the short-acting b2-agonists
salbutamol (8). This study showed that the onset of the
bronchodilating action of formoterol was roughly similar to
that of salbutamol.
The aim of this study was to investigate the bronchodi-
lating eect within the first 30min after inhalation of single
doses of formoterol administered via the inspiratory flow
driven multidose dry powder inhaler Turbuhaler. The
delivered doses 4?5 and 9 mg were compared with salbuta-
mol 100 and 200mg delivered via a pMDI and placebo in
adult patients with mild to moderate asthma.
A few studies have also made a comparison between the
onset of action of formoterol dry powder (Aerolizer1,
Novartis) and salbutamol in adult asthmatics (9–10). In
none of these studies a comparison has been made in the
same way as in the present day study i.e. measuring FEV1
already within the first 3min after inhalation.
Patients and Methods
PATIENTS
Patients of either gender aged 18 years or older were
included. They all had a diagnosis of asthma in a stable# 2000 HARCOURT PUBLISHERS LTD
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smokers or ex-smokers, who had stopped smoking at least 6
months prior to the first visit were to be included. They
should have a baseline FEV1 40% of predicted normal
value and a FEV1 of at least 1?5 l and a reversibility of at
least 15%, 15min after inhalation of 0?5 mg terbutaline
sulphate (Bricanyl1 Turbuhaler). Patients who showed any
signs of clinically relevant concomitant diseases were not
included.
Prior to each study day, the patients discontinued inhaled
short-acting b2-agonists for 6 h and inhaled ipratropium
bromide for 8 h. Disodium cromoglycate, anti-histamines
including ketotifen, inhaled and nasal glucocorticosteroids
(GCS) were permitted during the study, provided that the
doses were kept constant during 4 weeks prior to and
throughout the study. Oral b2-agonists, inhaled long-acting
b2-agonists, oral GCS, parenteral GCS, xanthines and oral
adrenergics were not allowed during the study.
STUDY DESIGN
The study was multi-centred and placebo-controlled with a
double-blind, double-dummy and cross-over design. The
study consisted of one screening visit and five study visits.
At the study visits, eligible patients were given either
formoterol 4?5mg or 9 mg via Turbuhaler, salbutamol 100 mg
or 200mg via a pMDI or placebo as single doses. On each
occasion the patients inhaled one dose from two identical
Turbuhaler inhalers and one dose from two pMDIs of the
same appearance to preserve the blinding of the study. The
doses used in the study are those recommended by the
manufacturers for salbutamol pMDI and formoterol
Turbuhaler. All four inhalations were performed within
1min. The inhalations also had to be performed between
07?00 and 10?00 hours and varying at most by 30min
between visits for an individual patient and separated by a
minimum of two days washout. Baseline FEV1 had to be
within12% of the FEV1 measured at the screening visit.
If not, the patients were asked to come back another day.
Three such attempts were allowed. The minimum duration
of the study was estimated to be 12 days, including a
post-study telephone contact for follow-up of adverse
events.
Patients were randomized in Latin squares of size five.
Stratification was made so that patients with even numbers
inhaled from the Turbuhaler first and patients with odd
numbers inhaled from the pMDI first. In order to ensure a
correct inhalation technique, all patients received instruc-
tions on how to use both the Turbuhaler and pMDI at their
first visit. At all visits, the patients also practised the
inhalation technique with placebo inhalers and all study
medication was taken under direct supervision of the
investigational team.
The study was approved by the National Health
Authorities in the Czech Republic and the local ethics
committees. The patients gave their informed consent
before enrolment in the study. The study was performed
in accordance with the principles stated in the Declaration
of Helsinki.ONSET OF ACTION—BRONCHODILATING
EFFECT
For determination of onset of action, FEV1 was measured
before and 1, 3, 5, 7, 10, 15, 20, 25 and 30min after
completed inhalation of the investigational products.
The higher value out of two measurements, recorded by
a Vitalograph1 Alpha (Vitalograph Inc., Buckingham,
England), was used. All measurements were made with the
same spirometer for each patient.
ONSET OF ACTION—SUBJECTIVE
EXPERIENCE
To evaluate the onsets of action, as judged by the patients,
a question was asked 3 min after inhalation at every study
visit. The question was: ‘Was the medication eective?’. The
patients were instructed to preferably answer yes or no to
the question. If they answered ‘not sure’, ‘don’t know’ etc,
the answer was registered as ‘no’.
STATISTICAL METHODS
Onset of action measured as FEV1
The primary variable was the FEV1-value at 3min after
inhalation of study drug. It was compared between
treatments by a multiplicative analysis of variance (ANO-
VA) model with patient, visit and treatment as fixed factors
and the pre-dose FEV1 values as a covariate. The time to
response, where response was defined as a 15% increase in
FEV1 from the pre-inhalation value, was also compared
between the active treatments, using survival analysis.
Dierences in the time-response profile were investigated
with an ANOVA model including patient, visit, treatment,
time and interaction treatment by time as factors and the
pre-dose FEV1 values as a covariate. In this analysis, only
the high dose of each substance was included.
Correlation between FEV1 and the response
experienced by the patients 3 min after inhalation
To investigate the correlation between the response
measured as FEV1 3min after drug administration and
the answer to the above question, a mixed eects logistic
regression model was applied using the General Estimating
Equations (GEE) technique.
Results
PATIENTS
Thirty-six Caucasian patients, of whom 16 were women,
with a mean age of 34 years (range 18–64 years)
participated in the study. They showed a mean baseline
FEV1 of 2?75 l (1?60–5?19 l) at study entry, which
corresponded to a mean FEV1 in % of predicted normal
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reversibility of 24?2% (14?6–47?1%).
Thirty-two patients were on regular treatment with
inhaled GCS, since at least 1 month prior to enrolment.
Twenty-six patients had one or more short-acting
b2-agonists, five patients used anti-histamines, two patients
nasal GCS, and one patient anti-cholinergics. Twenty-nine
patients had never smoked, seven patients were previous
smokers. Thirty patients had extrinsic asthma, two intrinsic
asthma, one chronic obstructive asthma and three unspe-
cified asthma. The duration of asthma ranged between 1
and 47 years. All 36 patients were enrolled at five dierent
centres in Czech Republic.
ONSET OF ACTION—BRONCHODILATING
EFFECT
All enrolled patients completed the study and they were all
considered fully eligible.
Figure 1 illustrates the mean value FEV1 curves, where
the FEV1-values are given as percentage change from
baseline.
The FEV1 value measured 3 min after inhalation revealed
no dierences between active treatments. All active treat-
ments gave a statistically significantly higher bronchodilat-TABLE 1. Analysis of time to response
Treatment
No. of
responders Me
Formoterol TBH 4?5 mg 26 11
Formoterol TBH 9mg 28 9
Salbutamol pMDI 100 mg 28 11
Salbutamol pMDI 200 mg 29 10
FIG. 1. Mean value FEV1 curves. Placebo (*);
Formoterol TBH 4?5mg (&); Formoterol TBH 9 mg (~);
Salbutamol pMDI 100 mg (+); Salbutamol pMDI 200mg
(^).ing eect than placebo; 10?0, 11?4% for salbutamol 100 and
200mg and 11?7, 11?8% for formoterol 4?5 and 9mg,
(P50?001 in all cases). The relative dierence vs. placebo
remained throughout the 30 min of measurement for all
active treatments except low dose salbutamol. A time-trend
test including the high dose of formoterol and salbutamol
was highly non-significant (P=0?94).
The median time to response ranged between 2?8 min
(formoterol 9 mg) and 5?3 min (salbutamol 200mg). No
dierence in this parameter between formoterol and
salbutamol was found. Results are given in Table 1.
ONSET OF ACTION—SUBJECTIVE
EXPERIENCE
The increase in FEV1 was generally much higher for the
patients who answered ‘yes’ to the question 3 min after
inhalation of study drug, than for the patients who
answered ‘no’. Mean increase in FEV1 (%) was 18?1
in the ‘yes’ group and 5?6 in the ‘no’ group, as shown in
Table 2.
Correlation between FEV1 and the response
experienced by the patients 3 min after inhalation
The estimated line became: Log odds =70?15+0?14*
FEV1.
The individual FEV1 values are plotted by answer (yes/
no) in Fig. 2 together with the model fit. In the figure, a
subdivision of the response in FEV1 is plotted together with
the resulting line. The slope was statistically dierent from 0
(95% CI 0?08–0?21; P50?001), showing a statistically
significant correlation.
Discussion
It is a common opinion that short-acting b2-agonists are
associated with a more rapid onset of action than long-
acting b2-agonists (11). In internationally accepted guide-
lines, short-acting b2-agonists are classified as symptom
‘relievers’ and are recommended to be used as needed in
patients with mild to more severe asthma or to prevent
obstruction induced by exercise or allergen provocation.
The long-acting b2-agonists are only recommended forTime to response (min)
an Median 95% CI (for median time)
?7 3?7 1?5 14?9
?4 2?8 1?0 6?3
?2 3?5 2?5 14?9
?0 5?3 0?8 9?1
TABLE 2. Descriptive statistics by answering category
Total
No.
Number of
Mean increase
FEV1 (%)
Range increase
FEV1 (%)Answer responders non-responders
Yes 137 68 69 18?1 74?6 72?3
No 43 4 39 5?6 723?9 28?3
FIG. 2. Correlation between response in FEV1 after 3min and the answer to the subjective question.
610 E. SEBEROVA´ AND A. ANDERSSONregular use in patients whose symptoms are not controlled
with inhaled GCS (1).
In the present study, no dierences were found between
formoterol and salbutamol regarding the bronchodilating
eect 3 min after inhalation and in the time to response.
These findings are in line with the results from other
studies, in which a comparison regarding the onset of
action between formoterol dry powder and salbutamol in
adults has been made. However, in these studies increase in
FEV1 from pre- to 5 min post-dose (9) or increase in specific
airway conductance (sGaw) (10) have been used. The same
results have also been shown in a study evaluating the
speeds of action of formoterol and salbutamol dry powder
in reversing methacholine-induced bronchoconstricton (12).
No other study, that we are aware of, has compared the
onset of action between formoterol Turbuhaler and
salbutamol pMDI.
The current data thus show that formoterol Turbuhaler
has a rapid onset of action, comparable to that of the short-
acting b2-agonist salbutamol, at recommended doses. These
data indicate that there is need for a revision of the opinion
that short-acting is equal to fast onset and long-acting isequal to slow-acting. Maybe a better classification would be
to describe the b2-agonists as fast- and slow-acting with
dierent duration of action.
The fast onset of action of formoterol via Turbuhaler, as
shown in the present and previous studies (6,7) would make
it possible to use it as needed for symptom relief in patients
with mild to moderate asthma. The use of formoterol
Turbuhaler on demand, in patients with moderate asthma,
has been evaluated in a recent study (13). In this study,
formoterol Turbuhaler prolonged the time to first asthma
exacerbation and improved asthma control compared with
terbutaline Turbuhaler.
One must also consider that true p.r.n. use of long-acting
b2-agonist could lead to a use of high doses in the case of an
acute bronchoconstriction. However the use of high doses
of formoterol has been documented in previous studies.
One study compared formoterol Turbuhaler to terbutaline
Turbuhaler in high doses (14). The results of this study
showed that daily doses up to and including 120 mg
formoterol (corresponding to 90mg delivered dose) were
safe and well tolerated in patients with chronic asthma
and without concomitant ischaemic heart diseases, using
OXIS1 ONSET OF ACTION COMPARED WITH SALBUTAMOL 611b2-agonists on a regular basis. Another study compared
formoterol Turbuhaler 90 mg (delivered dose) to terbutaline
Turbuhaler 10mg in patients with acute bronchoconstric-
tion (15). The results from this study also showed that
formoterol Turbuhaler in doses up to 90mg were safe and
well tolerated.
The data mentioned above together with the data from
the present study makes formoterol Turbuhaler a candidate
for true p.r.n. use. Further studies where formoterol
Turbuhaler is given p.r.n. compared to a short-acting
b2-agonist given p.r.n., in patients with mild persistent
asthma, would therefore be of great interest.
In addition to the objectively measured onset of action,
the subjective onset as judged by the patients was evaluated.
No other study has compared the correlation between the
subjective and objective time to onset of action, although
one non-placebo-controlled study has made a comparison
regarding the duration of eect after inhalation of
formoterol and salbutamol. This study indicated a good
correlation between subjective and objective duration of
eect (16). Data from the current study showed a positive
correlation between the subjective and the objective onset
of action. Thus, the fast onset of action of formoterol
Turbuhaler measured by FEV1 3min after inhalation was
also experienced by the patients, further indicating that
formoterol Turbuhaler given p.r.n. could be appreciated by
the patients.
In conclusion we have demonstrated that formoterol
administered via Turbuhaler at recommended doses, has as
rapid an onset of action as salbutamol administered via
pMDI at recommended doses.
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